
Orion S.A. Announces Upcoming CFO Retirement
"On behalf of our entire organization, we thank Jeff for his guidance and valuable contributions to Orion over the past three and a half years," Orion CEO Corning Painter said. 'Thanks to Jeff's leadership, we have exceptional finance and IT teams in place, and we are well-positioned for future growth.'
A comprehensive search will be launched to identify a successor. To ensure a smooth transition, Mr. Glajch will continue to support Orion through the end of 2025.
About Orion S.A.
Orion S.A. (NYSE: OEC) is a leading global supplier of carbon black, a solid form of carbon produced as powder or pellets. The material is made to customers' exacting specifications for tires, coatings, ink, batteries, plastics and numerous other specialty, high-performance applications. Carbon black is used to tint, colorize, provide reinforcement, conduct electricity, increase durability and add UV protection. Orion has four innovation centers and produces carbon black at 15 plants worldwide, offering the most diverse variety of production processes in the industry. The company's corporate lineage goes back more than 160 years to Germany, where it operates the world's longest-running carbon black plant. Orion is a leading innovator, applying a deep understanding of customers' needs to deliver sustainable solutions. For more information, please visit orioncarbons.com.
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including those related to our CFO transition, are statements of future expectations that are based on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include those factors detailed in our filings with the U.S. Securities and Exchange Commission. Additionally, new risk factors and uncertainties emerge from time to time and it is not possible to predict all risk factors and uncertainties, nor can we assess the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information, other than as required by applicable law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast
We recently published . Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices to a new 52-week low on Thursday, as investors soured on its lower earnings growth forecast. At intra-day trading, shares of Baxter International Inc. (NYSE:BAX) dropped to their lowest price of $21.47 before ending the day down by 22.42 percent at $21.76 apiece. In a call with analysts, Baxter International Inc. (NYSE:BAX) said it lowered its adjusted EPS to between $2.42 and $2.52 from the $2.47 to $2.55. Analysts expected $2.52 per share. 'While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks,' Baxter International Inc. (NYSE:BAX) CFO Joel Grade was quoted as saying, underscoring the demand weakness for IV fluids. Pixabay / Public Domain In the second quarter of the year, Baxter International Inc. (NYSE:BAX) swung to a net income attributable to shareholders of $91 million from a $314 million net loss in the same period last year. Net sales inched up by 4 percent to $2.8 billion from $2.69 billion. While we acknowledge the potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
AB InBev (BUD) Sheds 13% as Investors Panic Over Declining Volumes
We recently published . Anheuser-Busch InBev SA/NV (NYSE:BUD) is one of the worst-performing stocks on Thursday. Anheuser-Busch dropped for a second day on Thursday, shedding 13.3 percent to close at $57.67 apiece as investor sentiment was dampened by declining volumes despite growing its earnings year-on-year. In its updated report, Anheuser-Busch InBev SA/NV (NYSE:BUD) said that beer and non-beer volumes declined by 1.9 percent in the second quarter of the year at 143,347 versus 146,302 in the same period last year amid weak industries and performance in China and Brazil. The first half of the year also saw total volumes dipping 2 percent to 279,615 from 285,837 in the same comparable period. Despite the volume drop, Anheuser-Busch InBev SA/NV (NYSE:BUD) still recorded a 13.8-percent jump in net income attributable to shareholders, to $1.676 billion from $1.472 billion in the same period last year, while revenues ended flat at $15 billion. Photo by Gio Bartlett on Unsplash In the first half, attributable net income increased by 49 percent to $3.8 billion from $2.56 billion year-on-year, while revenues decreased by 4.3 percent to $28.6 billion from $29.88 billion. While we acknowledge the potential of BUD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer
We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 18.3% year-to-date on the back of several factors, such as troubles in China and the expiration of its KEYTRUDA patents. Cramer's previous comments about the firm have praised the firm's deal with Verona, through which it will get access to a chronic pulmonary obstructive disease (COPD) treatment. The acquisition is important as investors have grown concerned about Merck & Co., Inc. (NYSE:MRK)'s drug pipeline and wondered whether future drugs will mimic KEYTRUDA's success. Cramer discussed these factors: 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' Later in the day, he commented on Merck & Co., Inc. (NYSE:MRK)'s earnings: 'What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it. Small revenue miss, paired with an 11-cent earnings beat. Stock got hit, finishing the day down nearly 2% although it was a lot lower at one point. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio